Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 14 May 20 424B3 Prospectus supplement
- 10 Apr 20 EFFECT Notice of effectiveness
- 9 Apr 20 424B3 Prospectus supplement
- 6 Apr 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 6 Apr 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Mar 20 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 Mar 20 S-4/A Registration of securities issued in business combination transactions (amended)
- 4 Feb 20 S-4 Registration of securities issued in business combination transactions
QLGN similar filings
Filing view
External links
Exhibit 99.3
March 13, 2020
Ritter Pharmaceuticals, Inc.
1880 Century Park East, Suite 1000
Los Angeles, CA 90067
Consent to Reference in Joint Proxy and Consent Solicitation Statement/Prospectus
Ritter Pharmaceuticals, Inc. (the “Company”) has filed the Registration Statement on Form S-4 (Registration No. 333-236235), as amended, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the joint proxy and consent solicitation statement/prospectus included in such registration statement as a future member of the board of directors of the Company.
Sincerely, | |
/s/ Michael S. Poirier | |
Name: Michael S. Poirier |